CellGeneTech Inc. is a biopharmaceutical company established in Delaware, USA.
Accelerate the Development of Innovative Targeted Protein Degradation Therapies
CellgeneTech is a biopharmaceutical company dedicated to accelerating the development of innovative target Protein degradation therapies by leveraging a cross-border collaboration model and integrating the strengths of Asia Pacific innovation with US clinical development expertise.
About Us
Learn More
CellgeneTech Inc. is a US-based biotechnology company founded in 2024 with a mission to license high-potential targeted protein degradation (TPD) assets from the Asia-Pacific region and integrate US clinical development and business development expertise to develop BIC and FIC therapies to address unmet medical needs.
Our Strategy
Learn More
We are committed to addressing the significantly unmet medical needs in emerging markets, such as China and countries in Southeast Asia. Since our establishment, we have focused on establishing a platform to facilitate the localization and commercialization of drug candidates from US and European companies in Asia; the market potential in such countries remains substantial.
Get Connected
If you’d like to get in touch with us, you can send a message here.
